Nuo Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2018
Filed with the SEC on Aug 13, 2018 and accepted by EDGAR at Aug 13, 2018, 16:31 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2018-04-01 to 2018-06-30 | $138.3k | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 6 months2018-01-01 to 2018-06-30 | $298.3k | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months2018-04-01 to 2018-06-30 | $38.2k | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2018-01-01 to 2018-06-30 | $87.2k | us-gaap:CostOfRevenue |
| Gross profit | 3 months2018-04-01 to 2018-06-30 | $100.1k | us-gaap:GrossProfit |
| Gross profit | 6 months2018-01-01 to 2018-06-30 | $211.0k | us-gaap:GrossProfit |
| Research and development | 3 months2018-04-01 to 2018-06-30 | $140.1k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2018-01-01 to 2018-06-30 | $398.1k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2018-04-01 to 2018-06-30 | −$582.7k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2018-01-01 to 2018-06-30 | −$1.3m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2018-04-01 to 2018-06-30 | −$590.2k | us-gaap:NetIncomeLoss |
| Net income | 6 months2018-01-01 to 2018-06-30 | −$1.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2018-04-01 to 2018-06-30 | −$0.03 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2018-01-01 to 2018-06-30 | −$0.06 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2018-04-01 to 2018-06-30 | −$0.03 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2018-01-01 to 2018-06-30 | −$0.06 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2018-04-01 to 2018-06-30 | 22,931,191 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2018-01-01 to 2018-06-30 | 22,827,372 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2018-01-01 to 2018-06-30 | −$822.2k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2018-06-30 | $373.3k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2018-06-30 | $652.1k | us-gaap:AssetsCurrent |
| Total assets | At period end2018-06-30 | $823.3k | us-gaap:Assets |
| Current liabilities | At period end2018-06-30 | $1.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2018-06-30 | $1.1m | us-gaap:Liabilities |
| Shareholders' equity | At period end2018-06-30 | −$273.2k | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-18-015352. Last ingested by Listed: Nov 14, 2026, 23:44 ET. Listed shows no prices and gives no investment advice.